Abstract
Incidence of nonalcoholic steatohepatitis as a part of non-alcoholic fatty liver disease is still increasing and NASH and its complications are becoming one of the most common indications for liver transplantation. Screening of NASH in high risk subgroups and its diagnosis is still difficult with a need of liver biopsy.
Management of NASH is based on lifestyle intervention, diet and weight loss. Cornerstone of pharmacotherapy is the treatment of associated diabetes, arterial hypertension and dyslipidemy and there is an indication for the treatment with vitamin E and pioglitazon in some patients.
The prospective randomised trials with some new promising drugs are still ongoing and result are awaited.